Evidence map›Paper›PMID 42172791›Full record

ReviewTranslational oncology2026

Translational issues with phototherapy of cancer.

Maryam Ghafarkhani, Meghdad Abdollahpour-Alitappeh, Zahra Alizadeh, Solmaz Tabibi Azar, Mahdieh Nemati, Amir Zarebkohan, Daniel J Klionsky

Abstract readReview
In one paragraph

Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maryam GhafarkhaniDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, , Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Meghdad Abdollahpour-AlitappehDepartment of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Zahra AlizadehDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, , Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Solmaz Tabibi AzarDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
Mahdieh NematiDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, , Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Amir ZarebkohanDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, , Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: zarebkohana@tbzmed.ac.ir.
Daniel J KlionskyLife Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, MI, USA. Electronic address: klionsky@umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the most common and deadly diseases which has challenged human knowledge since its discovery. There are a variety of therapies, such as radiotherapy, chemotherapy, palliative surgery, medicine, and gene therapy, used for patients suffering from cancer, all of which represent, to some extent, a kind of failure. However, a number of novel strategies based on nanotechnology (including, photodynamic therapy [PDT] and photothermal therapy [PTT]) have been introduced in recent years, which appear to have the ability to be used as an auxiliary treatment for chemotherapy and radiotherapy in the future. Interestingly, cancer cells, in response to various therapeutic factors, can utilize certain cellular mechanisms and processes for their survival and growth. For example, macro autophagy/autophagy, can alter the cancer cell fate, from autophagic cell death to dormancy (as a key factor in tumor recurrence). Nonetheless, there have been conflicting conclusions regarding the interactions of phototherapy methods with cells as well as their wanted or unwanted impacts on these cells. In addition, there are complicated and controversial associations among the most common cell death mechanisms such as apoptosis, autophagy, and necrosis as well as tumor treatment and recurrence. The present review aims to describe various responses of cancer cells to photo-based therapy, which can control cell death or dormancy. Moreover, we discuss whether the incorrect application of various phototherapy parameters not only fails to treat and eradicate cancerous tumors, but also mediates the entry of tumor cells into the dormancy phase or even promotes a cancer flare up.

Indexed as

ApoptosisAutophagyCancerNanotechnologyNecrosisPDTPTT

Identifiers

PMID42172791
PMCPMC13224021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.